Targeting androgen receptor and PIP5K1A in prostate cancer cells using CRISPR-Cas9 genome editing tool

Hernández-Quiles, Miguel (2017) Targeting androgen receptor and PIP5K1A in prostate cancer cells using CRISPR-Cas9 genome editing tool. MRes thesis, University of Nottingham.

[img] PDF (Miguel Hernandez Quiles MRes AGPS Thesis) (Thesis - as examined) - Repository staff only until 12 July 2019. Subsequently available to Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (4MB)

Abstract

According to the World Cancer Research statistics, Prostate Cancer (PCa) accounts for 15% of all new cancer cases in men every year. More than 30% of treated patients will suffer disease recurrence and will develop Castration Resistant Prostate Cancer (CRPC), which no longer responds to androgen deprivation therapies. The mechanisms underlying the development of CRPC remain unclear. Androgen Receptor (AR) is highly expressed in prostate cancer cells, and plays an essential role in growth, survival and differentiation of prostate tumours. The aberrant activation of AR and AR-variants lacking the ligand binding domain (LBD), which is the therapeutic target of most PCa treatments, are characteristics of CRPC. In addition, recent studies suggest that PIP5K1A, a lipid kinase responsible for the synthesis of PIP2, might play an important role in PCa tumourogenesis and AR activation. In this study we used CRISPR-Cas9 genome editing technology to target AR and PIP5K1A in LNCaP C4-2 prostate cancer cells. Following cell sorting of GFP+ cells and clonal expansion, we successfully generated 9 mutant cell lines for PIP5K1A and 3 for AR. PCR Genotyping and DNA sequencing confirmed the presence of indels in targeted alleles in all of these clones, and Western Blots indicated that disruption of the targeted gene expression was achieved in several clones. Preliminary data showed AR depletion also reduces PIP5K1A expression, suggesting a regulatory pathway involving these genes. The AR and PIP5K1A mutant clones will be useful cell models to explore mechanisms involved in CRPC, and thus may aid the search of new therapies.

Item Type: Thesis (University of Nottingham only) (MRes)
Supervisors: Heery, David
Mongan, N.
Subjects: Q Science > QP Physiology > QP501 Animal biochemistry
R Medicine > RC Internal medicine > RC 254 Neoplasms. Tumors. Oncology (including Cancer)
Faculties/Schools: UK Campuses > Faculty of Science > School of Biosciences
Item ID: 39866
Depositing User: Hernandez Quiles, Miguel
Date Deposited: 30 Aug 2017 14:19
Last Modified: 12 Oct 2017 22:07
URI: http://eprints.nottingham.ac.uk/id/eprint/39866

Actions (Archive Staff Only)

Edit View Edit View